SubHero Banner

Invokamet® XR (canagliflozin/metformin extended-release) – New formulation approval

September 21, 2016 – Janssen announced the FDA approval of Invokamet XR (canagliflozin/metformin extended-release), indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) when treatment with both Invokana® (canagliflozin) and metformin is appropriate.

Download PDF